CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleRevenue is $19.44M, lower than 95% of all stocks globally
- FinancialsAltman Z-Score 11.26: safe zone
- Interpretations1 currently firing — 1
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
17.24BTWD541.14M · vs all stocks (USD)
Revenue (TTM)
619.48MTWD19.44M · vs all stocks (USD)
Profit Margin
-22.42%vs Biotechnology peers
52-Week Change
-18.75%vs all stocks
Market Capitalization
17.24BTWD541.14M · vs all stocks (USD)
Enterprise Value
15.84BTWD497.10M · vs all stocks (USD)
Forward P/E
-58.32xvs Biotechnology peers
Price to Sales (TTM)
27.27xvs Biotechnology peers
Price to Book (MRQ)
4.57xvs Biotechnology peers
Enterprise to Revenue
25.57xvs Biotechnology peers
Gross Margin
62.50%vs Biotechnology peers
Profit Margin
-22.42%vs Biotechnology peers
Operating Margin
-47.91%vs Biotechnology peers
Return on Assets (TTM)
-2.52%vs Biotechnology peers
Return on Equity (TTM)
-3.66%vs Biotechnology peers
Revenue (TTM)
619.48MTWD19.44M · vs all stocks (USD)
Revenue per Share (TTM)
2.29TWDUpdated Aug 20, 2026Quarterly Revenue Growth
13.30%vs Biotechnology peers
Gross Profit (TTM)
266.85MTWD8.37M · vs all stocks (USD)
EBITDA (TTM)
-39.10MTWD-1.23M · vs all stocks (USD)
Net Income (TTM)
-138.90MTWD-4.36M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
-5.76%vs Biotechnology peers
Operating Cash Flow (TTM)
155.12MTWD4.87M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
237.37MTWD7.45M · vs all stocks (USD)
Trailing Annual Dividend Rate
0.00TWDUpdated Aug 20, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Revenue
611.35MTWDFY2025 · Dec 31, 2025Cost of Goods Sold
351.90MTWDFY2025 · Dec 31, 2025Gross Profit
259.45MTWDFY2025 · Dec 31, 2025Operating Income
-194.65MTWD-6.11M · vs all stocks (USD)
Pre-tax Income
-167.78MTWDFY2025 · Dec 31, 2025Income Tax Expense
0.00TWDFY2025 · Dec 31, 2025Net Income
-167.78MTWDFY2025 · Dec 31, 2025EBIT
-157.06MTWDFY2025 · Dec 31, 2025EBITDA (Income Statement)
-3.45MTWDFY2025 · Dec 31, 2025Research & Development
381.84MTWDFY2025 · Dec 31, 2025Selling, General & Administrative
72.26MTWDFY2025 · Dec 31, 2025Non-operating Interest Income
28.94MTWDFY2025 · Dec 31, 2025Non-operating Interest Expense
10.71MTWDFY2025 · Dec 31, 2025Net Income from Continuing Operations
-167.78MTWDFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00TWDFY2025 · Dec 31, 2025Operating Cash Flow
-148.85MTWDFY2025 · Dec 31, 2025Free Cash Flow
-171.51MTWDFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
898.38MTWDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-167.78MTWDFY2025 · Dec 31, 2025Stock-based Compensation
8.77MTWDFY2025 · Dec 31, 2025Other Non-cash Items
-18.23MTWDFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
11.08MTWDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
17.31MTWDFY2025 · Dec 31, 2025Capital Expenditures
-22.67MTWDFY2025 · Dec 31, 2025Net Intangibles (CF)
-99.00KTWDFY2025 · Dec 31, 2025Purchase of Investments
-83.85MTWDFY2025 · Dec 31, 2025Sale of Investments
260.55MTWDFY2025 · Dec 31, 2025Other Investing Activity
92.00KTWDFY2025 · Dec 31, 2025Net Investing Cash Flow
154.12MTWDFY2025 · Dec 31, 2025Long-term Debt Payments
-27.24MTWDFY2025 · Dec 31, 2025Net Short-term Debt Issuance
0.00TWDFY2025 · Dec 31, 2025Other Financing Charges
-920.00KTWDFY2025 · Dec 31, 2025Net Financing Cash Flow
-19.38MTWDFY2025 · Dec 31, 2025Shares Outstanding
271.71MSharesUpdated Aug 20, 2026Float Shares
179.57MSharesUpdated Aug 20, 2026% Held by Insiders
18.76%vs all stocks
% Held by Institutions
18.75%vs all stocks
Total Cash (MRQ)
1.61BTWD50.44M · vs all stocks (USD)
Total Cash per Share (MRQ)
5.97TWDUpdated Aug 20, 2026Total Debt (MRQ)
450.00MTWD14.12M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.1224xvs Biotechnology peers
Current Ratio (MRQ)
15.48xvs Biotechnology peers
Book Value per Share (MRQ)
13.65TWDUpdated Aug 20, 2026Total Assets
4.81BTWD150.97M · vs all stocks (USD)
Total Current Assets
3.32BTWDFY2025 · Dec 31, 2025Total Liabilities
953.05MTWDFY2025 · Dec 31, 2025Total Non-current Assets
1.49BTWDFY2025 · Dec 31, 2025Total Non-current Liabilities
699.54MTWDFY2025 · Dec 31, 2025Total Current Liabilities
253.51MTWDFY2025 · Dec 31, 2025Cash & Cash Equivalents
898.38MTWDFY2025 · Dec 31, 2025Other Short-term Investments
872.35MTWDFY2025 · Dec 31, 2025Accounts Receivable
64.65MTWDFY2025 · Dec 31, 2025Inventory
827.73MTWDFY2025 · Dec 31, 2025Accounts Payable
81.00MTWDFY2025 · Dec 31, 2025Short-term Debt
30.12MTWDFY2025 · Dec 31, 2025Other Current Liabilities
4.16MTWDFY2025 · Dec 31, 2025Long-term Debt
463.00MTWDFY2025 · Dec 31, 2025Common Stock (Book)
2.73BTWDFY2025 · Dec 31, 2025Retained Earnings
-1.30BTWDFY2025 · Dec 31, 2025Total Shareholders' Equity
3.86BTWD121.06M · vs all stocks (USD)
52-Week Low
47.00TWDUpdated Aug 20, 202652-Week High
82.80TWDUpdated Aug 20, 202652-Week Change
-18.75%vs all stocks
50-Day MA
61.58TWDUpdated Aug 20, 2026200-Day MA
58.09TWDUpdated Aug 20, 2026Avg 10-Day Volume
1.50MSharesUpdated Aug 20, 2026Avg 30-Day Volume
1.30MSharesUpdated Aug 20, 2026Diluted EPS (TTM)
-0.5000TWDUpdated Aug 20, 20261 interpretation currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company financially stable?
Multi-Year Debt Decrease With Cash Near Total Debt And Equity
Long-term debt down in each of four years, and cash now covers most or all of what is left.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Structural Tensions
High gross margins eroded by operating costsNotable
Gross Margin: 0.62Profit Margin: -0.22
Financial Health
Altman Z-Score 11.26: safe zoneNotable
Altman Z-Score: 11.26
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Revenue is $19.44M, lower than 95% of all stocks globallySignificant
Revenue (USD): 19,440,678.019Global P5: 30,274,777.221
Companies that share the same coordination system — how they create, deliver, or capture value.
Guangdong Lifestrong Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Shandong Wohua Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Bliss GVS Pharma Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Hinova Pharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Pulike Biological Engineering Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Shanghai Sailun Biotech Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRule
NeuroPace Inc.
Tier 1ProductionApproval-Gated PipelineRule
Shanghai General Healthy Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Morepen Laboratories Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Relmada Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Companies that share active interpretations — structural patterns currently present in both stocks.
Nanjing Xinjiekou Department Store Co. Ltd.
1 interpretationMulti-Year Debt Decrease With Cash Near Total Debt And Equity
Wave Life Sciences Ltd.
1 interpretationMulti-Year Debt Decrease With Cash Near Total Debt And Equity
SM Entertainment Co., Ltd.
1 interpretationMulti-Year Debt Decrease With Cash Near Total Debt And Equity